
Alkermes plc (NASDAQ:ALKS - Free Report) - Analysts at Zacks Research raised their FY2025 earnings estimates for Alkermes in a note issued to investors on Tuesday, July 1st. Zacks Research analyst R. Department now forecasts that the company will earn $1.55 per share for the year, up from their prior forecast of $1.54. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes' FY2026 earnings at $1.98 EPS, Q1 2027 earnings at $0.32 EPS, Q2 2027 earnings at $0.48 EPS and FY2027 earnings at $1.68 EPS.
ALKS has been the topic of a number of other reports. Royal Bank Of Canada lifted their price target on Alkermes from $39.00 to $40.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. Needham & Company LLC began coverage on Alkermes in a research note on Wednesday, May 28th. They issued a "buy" rating and a $45.00 target price on the stock. UBS Group raised shares of Alkermes from a "neutral" rating to a "buy" rating and increased their price target for the company from $33.00 to $42.00 in a research report on Tuesday, June 17th. HC Wainwright restated a "neutral" rating on shares of Alkermes in a report on Friday, May 2nd. Finally, Wall Street Zen lowered shares of Alkermes from a "strong-buy" rating to a "buy" rating in a research note on Monday, May 5th. Three investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $40.00.
View Our Latest Report on ALKS
Alkermes Stock Performance
NASDAQ:ALKS traded down $0.25 during trading hours on Thursday, reaching $28.75. The company's stock had a trading volume of 1,122,189 shares, compared to its average volume of 1,737,488. The stock has a 50 day moving average price of $30.12 and a two-hundred day moving average price of $30.90. The company has a market capitalization of $4.74 billion, a P/E ratio of 13.76, a price-to-earnings-growth ratio of 1.79 and a beta of 0.44. Alkermes has a 12 month low of $22.90 and a 12 month high of $36.45.
Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.19). Alkermes had a net margin of 23.30% and a return on equity of 27.52%. The business had revenue of $306.51 million during the quarter, compared to the consensus estimate of $307.53 million. During the same quarter in the prior year, the firm posted $0.43 EPS. The company's revenue for the quarter was down 12.6% compared to the same quarter last year.
Institutional Trading of Alkermes
Several large investors have recently added to or reduced their stakes in the company. Proficio Capital Partners LLC acquired a new stake in shares of Alkermes during the fourth quarter worth about $940,000. Fisher Asset Management LLC raised its position in Alkermes by 27.1% during the 4th quarter. Fisher Asset Management LLC now owns 331,359 shares of the company's stock worth $9,530,000 after buying an additional 70,574 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in Alkermes by 558.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company's stock valued at $85,000 after acquiring an additional 2,502 shares during the period. Cornerstone Investment Partners LLC purchased a new stake in shares of Alkermes in the 4th quarter valued at $203,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Alkermes in the fourth quarter worth $12,293,000. Hedge funds and other institutional investors own 95.21% of the company's stock.
Insider Activity at Alkermes
In related news, SVP Christian Todd Nichols sold 3,334 shares of the company's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total value of $103,654.06. Following the transaction, the senior vice president directly owned 86,208 shares of the company's stock, valued at $2,680,206.72. This represents a 3.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.40% of the company's stock.
About Alkermes
(
Get Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured Articles

Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.